Infectious disease for the rhinologist.
Journal
Current opinion in otolaryngology & head and neck surgery
ISSN: 1531-6998
Titre abrégé: Curr Opin Otolaryngol Head Neck Surg
Pays: United States
ID NLM: 9417024
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
aheadofprint
Résumé
The purpose of this review is to summarize the recent literature relating to viral, fungal and bacterial infections and their interactions within the sinonasal tract in the past 18 months. Coronavirus disease 2019 (COVID-19)-associated olfactory dysfunction (OD) is variant dependent. Magnetic resonance imaging studies have found greater olfactory cleft opacification and higher olfactory bulb volume in post-COVID-19 OD. Olfactory training remains the mainstay of treatment, while platelet-rich plasma injections and ultramicronized palmitoylethanolamide and luteolin combination oral supplementation have shown early promise.Consensus statements on paranasal sinus fungal balls and acute invasive fungal sinusitis have been released.Studies on the nasal microbiome have reported Staphylococcus and Corynebacterium as the most abundant genera, with higher levels of Staphylococcus and Corynebacterium being found in patients with chronic rhinosinusitis (CRS) and healthy individuals respectively. However, there is conflicting evidence on the significance of biodiversity of the nasal microbiome found in CRS versus healthy patients. While the peak of the COVID-19 pandemic is behind us, its sequelae continue to pose treatment challenges. Further studies in OD have implications in managing the condition, beyond those afflicted post-COVID-19 infection. Similarly, more research is needed in studying the nasal microbiome and its implications in the development and treatment of CRS.
Identifiants
pubmed: 37997887
doi: 10.1097/MOO.0000000000000947
pii: 00020840-990000000-00100
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Gary JB, Gallagher L, Joseph PV, et al. Qualitative olfactory dysfunction and COVID-19: an evidence-based review with recommendations for the clinician. Am J Rhinol Allergy 2023; 37:95–101.
Boscolo-Rizzo P, Hummel T, Invitto S, et al. Psychophysical assessment of olfactory and gustatory function in postmild COVID-19 patients: A matched case-control study with 2-year follow-up. Int Forum Allergy Rhinol 2023; 13:1864–1875.
Said M, Luong T, Jang SS, et al. Clinical factors associated with lower health scores in COVID-19–related persistent olfactory dysfunction. Int Forum Allergy Rhinol 2022; 12:1242–1253.
Zyoud SeH, Shakhshir M, Koni A, et al. Olfactory and gustatory dysfunction in COVID-19: a global bibliometric and visualized analysis. Ann Oncol Rhinol Laryngol 2023; 132:164–172.
Haehner A, Marquardt B, Kardashi R, et al. SARS-CoV-2 leads to significantly more severe olfactory loss than other seasonal cold viruses. Life 2022; 12:461.
Vaira LA, Lechien JR, Deiana G, et al. Prevalence of olfactory dysfunction in D614G, alpha, delta and omicron waves: a psychophysical case–control study. Rhinology 2023; 61:32–38.
Butowt R, Bilińska K, von Bartheld C. Why does the omicron variant largely spare olfactory function? implications for the pathogenesis of anosmia in coronavirus disease. J Infect Dis 2022; 226:1304–1308.
Lechien JR, Radulesco T, Calvo-Henriquez C, et al. ACE2 & TMPRSS2 expressions in head & neck tissues: a systematic review. Head Neck Pathol 2021; 15:225–235.
Karimian A, Behjati M, Karimian M. Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2. Arch Virol 2022; 167:1931–1946.
Tan CJ, Tan BKJ, Tan XY, et al. Neuroradiological basis of COVID-19 olfactory dysfunction: a systematic review and meta-analysis. Laryngoscope 2022; 132:1260–1274.
Niesen M, Trotta N, Noel A, et al. Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell. Eur J Nucl Med Mol Imaging 2021; 48:1890–1901.
Yildirim D, Kandemirli SG, Tekcan Sanli DE, et al. A comparative olfactory MRI, DTI and fMRI study of COVID-19 related anosmia and post viral olfactory dysfunction. Acad Radiol 2022; 29:31–41.
Brudasca I, Lisan Q, Tournegros R, et al. Systematic MRI in persistent post-COVID-19 olfactory dysfunction should be reassessed. Int Forum Allergy Rhinol 2023; 13:285–287.
Mallick S, Ash J, Addison A, Philpott C. Ask the experts: an international consensus on managing post-infectious olfactory dysfunction including COVID-19. Curr Otorhinolaryngol Rep 2022; 10:433–439.
Lechner M, Liu J, Counsell N, et al. The COVANOS trial – insight into post-COVID olfactory dysfunction and the role of smell training. Rhinology 2022; 60:188–199.
Kattar N, Do TM, Unis GD, et al. Olfactory training for postviral olfactory dysfunction: systematic review and meta-analysis. Otolaryngol Head Neck Surg 2021; 164:244–254.
Webster KE, O’Byrne L, MacKeith S, et al. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev 2022; 9:Cd013877.
Yan CH, Jang SS, Lin H-FC, et al. Use of platelet-rich plasma for COVID-19–related olfactory loss: a randomized controlled trial. Int Forum Allergy Rhinol 2023; 13:989–997.
Di Stadio A, D’Ascanio L, Vaira LA, et al. Ultramicronized palmitoylethanolamide and luteolin supplement combined with olfactory training to treat post-COVID-19 olfactory impairment: a multi-center double-blinded randomized placebo- controlled clinical trial. Curr Neuropharmacol 2022; 20:2001–2012.
Centers for Disease Control and Prevention. Environmental infection control guidelines. Atlanta, GA: Centers for Disease Control and Prevention; 2019 [updated July 22; cited 2023 August 7]. Available at: https://www.cdc.gov/infectioncontrol/guidelines/environmental/appendix/air.html.
Gill AS, Kaur K, Shipman P, et al. Nasal endoscopy, room filtration, and aerosol concentrations during live outpatient encounters: a prospective, case–control study. Int Forum Allergy Rhinol 2022; 12:71–82.
Chavan RP, Ingole SM, Nazir HA, et al. Mucormycosis in COVID-19 pandemic: study at tertiary hospital in India. Eur Arch Otorhinolaryngol 2022; 279:3201–3210.
Sinha A, Bhaskar SMM. In-hospital prevalence of mucormycosis among coronavirus disease 2019 (COVID-19) patients and COVID-19 in mucormycosis: a systematic review and meta-analysis. Int Forum Allergy Rhinol 2022; 12:313–317.
Vadivel S, Gowrishankar M, Vetrivel K, et al. Rhino orbital cerebral mucormycosis in COVID-19 crisis. Indian J Otolaryngol Head Neck Surg 2023; 75: (Suppl 1): 1014–1020.
Sahu M, Shah M, Mallela VR, et al. COVID-19 associated multisystemic mucormycosis from India: a multicentric retrospective study on clinical profile, predisposing factors, cumulative mortality and factors affecting outcome. Infection 2023; 51:407–416.
Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe 2022; 3:e543–e552.
Sen M, Honavar SG, Bansal R, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol 2021; 69:1670–1692.
Honavar SG. Code mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol 2021; 69:1361–1365.
Seresirikachorn K, Png LH, Kondo M, et al. Endoscopic-modified medial maxillectomy for the nonfunctioning maxillary sinus. Am J Rhinol Allergy 2023; 37:611–615.
Seresirikachorn K, Kondo M, Png LH, et al. Prelacrimal approach to maxillary sinus pathology. Am J Rhinol Allergy 2023; 37:369–373.
Saibene AM, Allevi F, Calvo-Henriquez C, et al. Comprehensive management of paranasal sinus fungus balls: a Young-IFOS consensus statement. Int Forum AllergyRhinol 2023; 13:877–885.
Roland LT, Humphreys IM, Le CH, et al. Diagnosis, prognosticators, and management of acute invasive fungal rhinosinusitis: multidisciplinary consensus statement and evidence-based review with recommendations. Int Forum Allergy Rhinol 2023; 13:1615–1714.
Zhu Z, Lan J, Wei R, et al. Microbiome and Th cytokines association in chronic rhinosinusitis with or without nasal polyp. Laryngoscope Investig Otolaryngol 2023; 8:335–345.
Bartosik TJ, Campion NJ, Freisl K, et al. The nasal microbiome in patients suffering from nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids. Front Immunol 2023; 14:1112345.
Shu M, Wang Y, Yu J, et al. Fermentation of Propionibacterium acnes, a commensal bacterium in the human skin microbiome, as skin probiotics against methicillin-resistant Staphylococcus aureus. PLoS One 2013; 8:e55380.
Lee JT, Simpson CA, Yang HH, et al. Fungal and bacterial microbiome in sinus mucosa of patients with and without chronic rhinosinusitis. Laryngoscope 2023; 10.1002/lary.30941.
doi: 10.1002/lary.30941
Liang Y, Xie R, Xiong X, et al. Alterations of nasal microbiome in eosinophilic chronic rhinosinusitis. J Allergy Clin Immunol 2023; 151:1286–1295. e2.
Rom D, Sit A, Alvarado R, et al. Bacterial colonization differences between central compartment atopic disease and eosinophilic chronic rhinosinusitis. Int Forum Allergy Rhinol 2023; 13:1978–1981.
Hale SJM, Lux CA, Kim R, et al. In vitro nasodine can be an effective antibiofilm agent for biofilms that may cause CRS. Laryngoscope 2023; 133:2490–2495.
Hon K, Liu S, Cooksley C, et al. Low pH nasal rinse solution enhances mupirocin antimicrobial efficacy. Rhinology 2022; 218:218–228.
Mårtensson A, Cervin-Hoberg C, Huygens F, et al. Upper airway microbiome transplantation for patients with chronic rhinosinusitis. Int Forum Allergy Rhinol 2023; 13:979–988.
Latek M, Lacwik P, Molinska K, et al. Effect of an intranasal corticosteroid on quality of life and local microbiome in young children with chronic rhinosinusitis: a randomized clinical trial. JAMA Pediatr 2023; 177:345–352.